Geisinger partners with EarlySign for AI algorithms to spot chronic disease

Geisinger and its Steele Institute for Health Innovation are collaborating with Medial EarlySign to implement machine learning technology for detection and prevention of chronic and high-cost diseases.

WHY IT MATTERS Together, the vendor and the pioneering health system will develop and deploy several AI tools to better identify patients who might be at risk of a range of chronic conditions.

To start, EarlySign’s LGI-Flag technology, which analyzes data such as variations in routine blood tests, will be deployed to help Geisinger clinicians spot people at higher risk for significant lower gastrointestinal disorders.

That software will form the basis for the two to explore other opportunities to tackle other acute and chronic diseases, officials said, with EarlySign able to avail itself of Geisinger’s advanced IT infrastructure, unique datasets and top care teams.

“EarlySign’s technology and the LGI-Flag solution will potentially assist our teams to more quickly identify significant lower GI disorders and intervene earlier than we historically have been able to,” Dr. Keith A. Boell, associate chief quality officer at Geisinger, said in a statement. “We look forward to advancing our use of this technology while leveraging our experience to help more patients benefit from these life-changing medical advances.”